Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery

Inclusion Criteria: * ≥18 months status-post RYGB * BMI 27 kg/m2 or greater in the presence of at least one weight-related comorbid condition * BMI 30 kg/m2 or greater * Regain of ≥10% of maximum TBWL post-RYGB * Ability to provide informed consent before any trial-related activities * Express willingness to follow protocol requirements Exclusion Criteria: * Pregnancy at time of enrollment * Intention of becoming pregnant or breast feeding in the next 12 months * Females of childbearing potential who are not using adequate contraceptive methods * Presence of acute psychiatric problems or immaturity which would compromise cooperation with the study protocol * Presence of biliary disease * Known or suspected allergy to liraglutide or any product components * Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 * History of pancreatitis * History of alcoholism * History of Type 1 DM (Diabetes Mellitus) * History of previous bariatric surgery other than RYGB except h/o LAGB and band removal. * \>10 years status-post RYGB * \< 25% TBWL at post-RYGB weight nadir * \>50% post-operative TBWL at time of screening * Simultaneous use of any weight loss medications * Use of insulin at the time of enrollment * Current use of any GLP-1 agonist medication * History of taking any GLP-1 agonist medication * Participation in another ongoing clinical study * Conditions that, in the opinion of the principal investigator, may jeopardize the patient's well-being and/or the soundness of this clinical study